Cost-Effectiveness of Hypertension Treatment with Diabetes Mellitus Complications in Hospitalized Patients at Berkah Pandeglang Regional Hospital Cost-Effectiveness of Hypertension Treatment with Diabetes Mellitus Complications in Hospitalized Patients at Berkah Pandeglang Regional Hospital
Bilah Samping Artikel
Isi Artikel Utama
Abstrak
Hypertension with diabetes mellitus (DM) is a frequent comorbidity that increases clinical complexity and healthcare expenditures. Various antihypertensive and antidiabetic combination therapies are used in hospitalized patients, making pharmacoeconomic evaluation necessary to determine the most cost-effective treatment option. This study aimed to evaluate the cost-effectiveness of hypertension treatment with diabetes mellitus complications in hospitalized patients at Berkah Pandeglang Regional Hospital. This was a non-experimental observational study with a retrospective design using secondary data from medical records and hospital billing data of hospitalized patients diagnosed with hypertension and DM in 2024. Direct medical costs and clinical effectiveness outcomes, including blood pressure control, blood glucose levels, and length of stay (LOS), were analyzed. Cost-effectiveness was assessed using the Average Cost-Effectiveness Ratio (ACER) and Incremental Cost-Effectiveness Ratio (ICER). A total of 9 patients met the inclusion criteria. Of these, 5 patients received captopril, amlodipine, and metformin, while 4 patients received amlodipine, candesartan, bisoprolol, metformin, and glimepiride. The combination therapy of captopril and amlodipine with metformin showed the lowest ACER value (IDR 25,941), indicating the most cost-effective regimen. Another combination consisting of amlodipine, candesartan, and bisoprolol with metformin and glimepiride had a higher ACER value (IDR 82,621). Both regimens were located in quadrant II of the cost-effectiveness plane, representing lower costs with higher effectiveness. The combination of captopril, amlodipine, and metformin was identified as the most cost-effective therapy for hospitalized patients with hypertension and diabetes mellitus complications at Berkah Pandeglang Regional Hospital.
Unduhan
Rincian Artikel
Artikel ini berlisensiCreative Commons Attribution-ShareAlike 4.0 International License.
Seorang penulis yang menerbitkan dalam PharmaCine: Journal of Pharmacy, Medical and Health Science menyetujui persyaratan berikut:
- Penulis memegang hak cipta dan memberikan hak publikasi pertama kepada jurnal dengan karya tersebut secara bersamaan dilisensikan di bawah Lisensi Creative Commons Attribution-ShareAlike 4.0 International License yang memungkinkan orang lain untuk berbagi karya tersebut dengan pengakuan atas kepenulisan karya tersebut dan publikasi awal di jurnal ini
- Penulis dapat mengadakan perjanjian kontrak tambahan yang terpisah untuk distribusi non-eksklusif dari karya versi terbitan jurnal (misalnya, mempostingnya ke repositori institusi atau menerbitkannya dalam buku), dengan pengakuan atas publikasi awalnya pada tahun jurnal ini.
- Penulis diizinkan dan didorong untuk memposting karya mereka secara online (misalnya, di repositori institusi atau di situs web mereka) sebelum dan selama proses penyerahan, karena hal ini dapat mengarah pada pertukaran yang produktif, serta kutipan karya yang diterbitkan lebih awal dan lebih banyak (Lihat Pengaruh Akses Terbuka).
PharmaCine : Journal of Pharmacy, Medical and Health Science oleh https://jhs.unsika.ac.id/ dilisensikan berdasarkan Creative Commons Attribution-ShareAlike 4.0 International License.
Anda bebas untuk:
- Bagikan, salin, dan distribusikan ulang materi dalam media atau format apa pun
- Mengadaptasi, mencampur ulang, mengubah, dan mengembangkan materi untuk tujuan apa pun, bahkan untuk tujuan komersial.
- Pemberi lisensi tidak dapat mencabut kebebasan ini selama Anda mengikuti ketentuan lisensi.
Referensi
Abdus, M., Bhuiyan, S., Wara, U., Chowdhury, K., & Sharker, M. A. (2025). European Journal of Cardiovascular Medicine ( EJCM ) Comorbidity Profile of Hypertension and Diabetes Among Middle-Aged and Elderly Patients in a Clinical Setting. (10), 418–422.
American Diabetes Association Professional Practice Committee. (2024). 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care, 47(Suppl 1), S179–S218. https://doi.org/10.2337/dc24-S010
Anggraini, D. W., Nurmainah, N., & Rizkifani, S. (2023). Analisis Efektivitas Biaya Antihipertensi Amlodipin Tunggal dan Kombinasi pada Pasien Hipertensi dengan Diabetes Melitus Tipe II Rawat Jalan di Rumah Sakit di Kota Pontianak. Jurnal Pharmascience, 10(2), 329. https://doi.org/10.20527/jps.v10i2.16014
Bang, H., & Zhao, H. (2012). Average cost-effectiveness ratio with censored data. Journal of Biopharmaceutical Statistics, 22(2), 401–415. https://doi.org/10.1080/10543406.2010.544437
Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economic Evaluation of Health Care Programmes (4th ed.). Oxford University Press PL - Oxford.
Dung, L. D., & Long, G. T. (2016). Gender differences in prevalence and associated factors of multi-morbidity among older persons in Vietnam. International Journal on Ageing in Developing Countries, 1(2), 113–132.
Gunes, Y. (2025). A brief approach to hypertension in type 2 diabetes mellitus. Exploration of Endocrine and Metabolic Diseases, 1–13. https://doi.org/10.37349/eemd.2025.101422
Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005). Global burden of hypertension: analysis of worldwide data. The Lancet, 365(9455), 217–223. https://doi.org/10.1016/S0140-6736(05)17741-1
King, J. B., An, J., Bellows, B. K., Cohen, J. B., Commodore-Mensah, Y., Ghazi, L., Langford, A. T., Brook, R. D., & Cardiology, on behalf of the A. H. A. C. on H. C. on C. and S. N. and C. on C. (2026). Single-Pill Combination Therapy for the Management of Hypertension: A Scientific Statement From the American Heart Association. Hypertension, 0(0). https://doi.org/10.1161/HYP.0000000000000258
Kiss, N., Hiesmayr, M., Sulz, I., Bauer, P., Heinze, G., Mouhieddine, M., Schuh, C., Tarantino, S., & Simon, J. (2021). Predicting Hospital Length of Stay at Admission Using Global and Country-Specific Competing Risk Analysis of Structural, Patient, and Nutrition-Related Data from nutritionDay 2007-2015. Nutrients, 13(11). https://doi.org/10.3390/nu13114111
Mohan, R., Shantini, D., Jawahir, S., Manual, A., Abdul Mutalib, N. E., Mohd Noh, S. N., Ab Rahim, I., Ab Hamid, J., & Amer Nordin, A. (2025). Gender differences in health-seeking behaviour: insights from the National Health and Morbidity Survey 2019. BMC Health Services Research, 25(1), 900. https://doi.org/10.1186/s12913-025-13020-0
Muir, A. J., Sanders, L. L., Wilkinson, W. E., & Schmader, K. (2001). Reducing medication regimen complexity: a controlled trial. Journal of General Internal Medicine, 16(2), 77–82. https://doi.org/10.1046/j.1525-1497.2001.016002077.x
Murru, V., Belfiori, E., Sestu, A., Casanova, A., Serra, C., & Scuteri, A. (2025). Patterns of comorbidities differentially impact on in-hospital outcomes in heart failure patients. BMC Geriatrics, 25(1), 371. https://doi.org/10.1186/s12877-025-06002-8
Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2026). Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold. New England Journal of Medicine, 371(9), 796–797. https://doi.org/10.1056/NEJMp1405158
Putri, A. S., & Dyahariesti, N. (2021). Analisis Efektivitas Biaya Kombinasi Obat Antihipertensi Pada Pasien Rawat Inap Di RS PKU Muhammadiyah Yogyakarta Tahun 2020. Indonesian Journal of Pharmacy and Natural Product, 4(2), 95–106. https://doi.org/10.35473/ijpnp.v4i2.1296
Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-Llimos, F. (2021). Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions. Pharmacy Practice, 19(1), 1–10. https://doi.org/10.18549/PharmPract.2021.1.2302
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., Wainford, R. D., Williams, B., & Schutte, A. E. (2020). 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75(6), 1334–1357. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026
Wang, W., Wan, Q., Wang, S., Ning, G., Bi, Y., Liu, L., Liu, Y., Liu, Y., Li, X., Li, T., Wu, X., Wu, S., Sha, Y., Zhang, Y., Chen, R., Zheng, H., Zhao, D., Hu, L., Duan, P., … Pan, H. (2025). Management Guidelines for Diabetic Patients With Hypertension. Journal of Diabetes, 17(6), e70093. https://doi.org/10.1111/1753-0407.70093
World Health Organization. (2025). Hypertension.
Zheng, W.-X., Liao, P., Luo, L.-L., Gu, J., Du, L., & Tian, Y.-Z. (2025). Risk factors for comorbid hypertension in elderly patients with type 2 diabetes. American Journal of Translational Research, 17(8), 6453–6461. https://doi.org/10.62347/UCOV1190